Abstract
Bacteriological and clinical studies were carried out on Sultamicillin, a new oral antibiotics, which combined ampicillin (ABPC) and Sulbactam (SBT), a new β-lactamase inhibitor, with ester-bond.
Antimicrobial activities of Sultamicillin against S. aureus, E. coil, K. pneumoniae, indole positive Proteusand H. influenzae were superior to those of AM PC. But there was no remarkable combination effect on MIC for P. mirabilis. The activities of Sultamicillin was almost equal to those of BRL-25000.
A total of 20 cases (18 with respiratory tract, 1 with urinary tract and 1 with skin infections) were treated with 3 or 4 tablets per day for 3 to 14 days. Clinical efficacy was evaluated as good in 16, fair in 2 and poor in 2. The overall efficacy rate was therefore 80.0%.
As to the side effects, anorexia and abdominal pain in 2 cases, diarrhea in one case, and nausea and vomiting in one case were observed And in clinical laboratory data, slight and transient eosinophilia was observed in one patient after the treatment.
